Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Eur Acad Dermatol Venereol ; 38(5): 904-909, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38112226

RESUMEN

BACKGROUND: Adalimumab monotherapy for hidradenitis suppurativa (HS) is often insufficient with a maximum clinical efficacy of 60% in Hidradenitis Suppurativa Clinical Response (HiSCR) and limited effect on draining tunnels. Data suggest that adalimumab therapy could be improved by concomitant antibiotics. OBJECTIVE: To compare the clinical effectiveness of adalimumab with clindamycin and rifampicin versus adalimumab monotherapy after 12 weeks. METHODS: This retrospective study included patients who started adalimumab with additional clindamycin and rifampicin and patients treated with adalimumab monotherapy, matched on sex and refined Hurley score. The primary outcome measure was the difference in change in the International Hidradenitis Suppurativa Severity Score System (IHS4) at 12 weeks. RESULTS: In total, 62 patients were included in the combination therapy group (n = 31) and adalimumab monotherapy group (n = 31), showing comparable IHS4 scores; 32.5 versus 29, p = 0.87 at baseline respectively. The combination therapy demonstrated greater clinical effectiveness expressed in median IHS4 improvement (-20 vs. -9, p < 0.001), IHS4-55 (74% vs. 36%, p = 0.002), median draining tunnel reduction (-4 vs. -2, p < 0.001) and pain response (47% vs. 27%, p = 0.02). CONCLUSION: Adalimumab initiated with clindamycin and rifampicin shows greater clinical effectiveness than adalimumab monotherapy. An important difference in effect was observed in the decrease of draining tunnels, addressing a serious limitation of adalimumab monotherapy.


Asunto(s)
Adalimumab , Clindamicina , Quimioterapia Combinada , Hidradenitis Supurativa , Rifampin , Humanos , Hidradenitis Supurativa/tratamiento farmacológico , Adalimumab/uso terapéutico , Adalimumab/administración & dosificación , Rifampin/uso terapéutico , Rifampin/administración & dosificación , Clindamicina/uso terapéutico , Clindamicina/administración & dosificación , Estudios Retrospectivos , Femenino , Masculino , Adulto , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Antibacterianos/uso terapéutico , Antibacterianos/administración & dosificación , Resultado del Tratamiento
2.
Nat Commun ; 12(1): 4692, 2021 Aug 03.
Artículo en Inglés | MEDLINE | ID: mdl-34344881

RESUMEN

The plasma-induced charge of non-spherical microparticles is a crucial parameter in complex plasma physics, aerosol science and astrophysics. Yet, the literature describes this charge by two competing models, neither of which has been experimentally verified or refuted. Here we offer experimental proof that the charge on a two-particle cluster (doublet) in the spatial afterglow of a low-pressure plasma equals the charge that would be obtained by the smallest enclosing sphere and that it should therefore not be based on its geometrical capacitance but rather on the capacitance of its smallest enclosing sphere. To support this conclusion, the size, mass and charge of single particles (singlets) and doublets are measured with high precision. The measured ratio between the plasma-afterglow-induced charges on doublets and singlets is compared to both models and shows perfect agreement with the predicted ratio using the capacitance of the smallest enclosing sphere, while being significantly dissimilar to the predicted ratio based on the particle's geometrical capacitance.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...